AKTX EBITDA | Akari Therapeutics, Plc

Akari Therapeutics, Plc (AKTX) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$4.60M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$15.76M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$7.40M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$3.12M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2014-12-31 to 2024-12-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$4.60M	(m)	(m)	(m)	(m)	-$3.11M*	(m)	$2.08M	$2.52M	$0.00*
2026-03-31	Reported	(m)	-$15.76M	(m)	(m)	(m)	(m)	-$2.49M	(m)	$1.46M	$2.17M	-$859.00K
2025-09-30	Reported	(m)	-$7.40M	(m)	(m)	(m)	(m)	-$2.12M*	(m)	$249.00K	$1.98M	-$1.09M
2025-06-30	Reported	(m)	-$3.12M	(m)	(m)	(m)	(m)	-$3.26M*	(m)	$667.00K	$2.45M	$0.00
2025-03-31	Reported	(m)	-$3.52M	(m)	(m)	(m)	(m)	-$2.15M	(m)	$813.00K	$2.71M	$0.00
2024-12-31	Reported	-$5.28M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$2.93M*	-$2.93M	$0.00*	(m)	(m)	(m)	-$1.49M*	(m)	$143.00K	$1.71M	(m)
2024-06-30	Reported	-$7.45M*	-$7.45M	$0.00*	$0.00	(m)	(m)	-$4.89M*	(m)	$3.31M	$2.24M	$0.00
2024-03-31	Reported	-$5.98M	(m)	(m)	(m)	(m)	(m)	-$4.04M	(m)	$2.28M	$3.71M	$0.00
2023-12-31	Reported	-$5.09M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$2.51M*	-$2.51M	$1.00K*	(m)	(m)	(m)	-$9.35M*	(m)	-$314.00K	$2.82M	(m)
2023-06-30	Reported	-$2.67M*	-$2.67M	$1.00K*	$0.00	(m)	(m)	$2.21M*	(m)	$371.15K	$3.09M	$0.00
2023-03-31	Reported	-$4.59M	(m)	(m)	(m)	(m)	(m)	-$4.88M	(m)	$1.73M	$2.86M	(m)
2022-06-30	Reported	(m)	-$5.82M	(m)	(m)	(m)	(m)	(m)	(m)	$2.85M	$2.97M	(m)
2021-06-30	Reported	(m)	-$4.33M	(m)	(m)	(m)	(m)	(m)	(m)	$2.18M	$2.15M	(m)
2020-12-31	Reported	-$6.89M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$245.90K*	-$246.88K	$986.00*	(m)	(m)	(m)	-$704.17K*	(m)	(m)	$1.84M	(m)
2020-06-30	Reported	-$5.91M*	-$5.91M	$3.04K*	(m)	(m)	(m)	-$4.27M*	(m)	$3.02M	$2.89M	(m)
2020-03-31	Reported	-$4.92M*	-$4.93M	$3.88K	(m)	(m)	(m)	-$7.74M	(m)	(m)	$2.19M	(m)
2019-12-31	Reported	-$7.82M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$3.11M*	-$3.12M	$4.63K*	(m)	(m)	(m)	-$4.91M*	(m)	(m)	$1.35M	(m)
2019-06-30	Reported	-$6.03M*	-$6.03M	$4.70K*	(m)	(m)	(m)	-$4.77M*	(m)	$3.59M	$2.44M	(m)
2019-03-31	Reported	$17.53K*	$11.96K	$5.57K	(m)	(m)	(m)	$228.94K	(m)	(m)	$2.31M	(m)
2018-06-30	Reported	(m)	-$7.98M	(m)	(m)	(m)	(m)	(m)	(m)	$5.12M	$2.86M	(m)
2017-06-30	Reported	(m)	-$7.35M	(m)	(m)	(m)	(m)	(m)	(m)	$3.78M	$3.57M	(m)
2016-06-30	Reported	(m)	-$7.52M	(m)	(m)	(m)	$5.90K*	(m)	(m)	$5.44M	$2.08M	(m)
2016-03-31	Reported	(m)	-$3.85M	(m)	(m)	(m)	$42.08K	-$7.44M	(m)	$1.50M	$2.35M	$0.00
2015-09-30	Reported	(m)	-$23.33M	(m)	(m)	(m)	(m)	$5.30M*	(m)	$1.31M	$2.73M	$0.00
2015-06-30	Reported	(m)	-$1.31M	(m)	(m)	(m)	$0.00*	-$1.51M*	(m)	$1.00M	$310.83K	$0.00
2015-03-31	Reported	(m)	-$1.65M	(m)	(m)	(m)	$0.00	-$1.99M	(m)	$1.55M	$99.68K	$0.00
2014-09-30	Reported	(m)	-$218.03K	(m)	(m)	(m)	(m)	$3.57M*	(m)	$162.57K	$55.45K	$0.00
2014-06-30	Reported	(m)	-$2.33M	(m)	(m)	(m)	(m)	-$2.33M*	(m)	$1.54M	$790.00K	$0.00
2014-03-31	Reported	(m)	-$1.88M	(m)	(m)	(m)	(m)	-$2.05M	(m)	$800.00K	$1.08M	$0.00

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$17.27M	(m)	(m)	(m)	(m)	-$10.57M	(m)	$2.81M	$9.28M	-$1.00M
2024-12-31	Reported	-$21.63M	(m)	(m)	(m)	(m)	(m)	-$12.55M	(m)	$6.98M	$9.66M	$0.00
2023-12-31	Reported	-$16.8M	(m)	(m)	(m)	(m)	$0.00	-$16.43M	(m)	$5.45M	$11.36M	$0.00
2022-12-31	Reported	-$23.08M	(m)	(m)	(m)	(m)	$142.25K	-$7.49M	(m)	$3.92M	$13.53M	-$74.00K
2021-12-31	Reported	-$17.21M	(m)	(m)	(m)	(m)	(m)	-$18.85M	(m)	$9.13M	$8.08M	$0.00
2020-12-31	Reported	-$17.97M	(m)	(m)	(m)	(m)	(m)	-$16.95M	(m)	$8.82M	$9.16M	$0.00
2019-12-31	Reported	-$16.94M	(m)	(m)	(m)	(m)	$0.00	-$12.92M	(m)	$8.74M	$8.22M	$0.00
2018-12-31	Reported	-$20.75M	(m)	(m)	(m)	(m)	$0.00	-$22.77M	(m)	$11.80M	$11.69M	$0.00
2017-12-31	Reported	-$37.74M	(m)	(m)	(m)	(m)	$36.88K	-$31.60M	(m)	$23.29M	$11.80M	$0.00
2016-12-31	Reported	-$27.21M	(m)	(m)	(m)	(m)	$54.75K	-$24.62M	(m)	$17.31M	$9.94M	$0.00
2015-12-31	Reported	-$30.57M	(m)	(m)	(m)	(m)	$10.56K	-$4.97M	(m)	$5.80M	$5.50M	$0.00
2014-12-31	Reported	-$1.91M	(m)	(m)	(m)	(m)	$0.00	-$1.48M	(m)	$1.62M	$303.10K	$0.00
2013-12-31	Reported	(m)	-$3.61M	(m)	(m)	(m)	$0.00	-$5.45M	(m)	$1.28M	$2.33M	(m)
2012-12-31	Reported	(m)	-$3.67M	(m)	(m)	(m)	$0.00	-$2.13M	(m)	$1.48M	$2.18M	(m)
2011-12-31	Reported	(m)	-$2.25M	(m)	(m)	(m)	$0.00	-$1.01M	(m)	$841.00K	$1.41M	(m)
2010-12-31	Reported	(m)	-$792.00K	(m)	(m)	(m)	$0.00	-$366.00K	(m)	$247.00K	$545.00K	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
ELI LILLY & Co (LLY)	United States	$1,113.804B	42.28
JOHNSON & JOHNSON (JNJ)	United States	$652.528B	29.10
AbbVie Inc. (ABBV)	United States	$468.180B	70.37
Merck & Co., Inc. (MRK)	United States	$365.215B	99.96
ABBOTT LABORATORIES (ABT)	United States	$176.045B	28.47
PFIZER INC (PFE)	United States	$162.042B	31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)	United States	$132.481B	28.56
BRISTOL MYERS SQUIBB CO (BMY)	United States	$125.637B	12.67
REGENERON PHARMACEUTICALS, INC. (REGN)	United States	$74.751B	21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)	United States	$33.420B	54.94